

Focal Segmental Glomerulosclerosis (FSGS) Clinical Trial Medication Stop Point Form (Form # 72)

Once a Stop Point has been confirmed by Clinical Management Subcommittee Review, a measurement of serum SMA 18, cyclosporine level, CBC, lipids, and Up/c will be obtained. Refer to the Protocol section 11.2 for further information pertaining to Medication Stop Points.

Reason for Stop Point:

5. a. Pregnancy(0 = no, 1 = yes) PREG
1) Date of positive pregnancy test(dd/mmm/yyyy) ____ / ____ / ____ PREGDT

b. Decline in GFR: 50% decline from baseline in estimated GFR
to GFR \leq 75 ml/min/1.73m²(0 = no, 1 = yes) DECGFR
1) Date of blood specimen collection
that determined Stop Point.....(dd/mmm/yyyy) ____ / ____ / ____ DRAWDT

c. Does the participant have kidney failure?(0 = no, 1 = yes) ESRD
If yes and if applicable, complete an SAE (F61) and hospitalization (F62) form
1) If yes, patient's ESRD treatment modality.....
1 = hemodialysis 4 = untreated (refusing dialysis)
2 = peritoneal dialysis 8 = not applicable
3 = kidney transplant 9 = unknown

2) Date of ESRD onset.....(dd/mmm/yyyy) ____ / ____ / ____ ESRDDT

d. Medication related toxicity(0 = no, 1 = yes) MEDTOX
If yes, complete the appropriate toxicity CRF

e. Other(0 = no, 1 = yes) OTHER
1) if 5e, "Other" is yes, specify..... OTHSPE

6. Since the participant's last visit, did an Adverse Event possibly related to
study drug(s) occur?(0 = no, 1 = yes) AEOCC
If yes, complete the appropriate AE form(s) – F60 and/or F61

7. Has the participant been hospitalized since the last visit?(0 = no, 1 = yes) HOSPNY
If yes, complete F62 (Hospitalization Form) and F61 (SAE)

8. Date Clinical Management Committee confirmed
Stop Point.....(dd/mmm/yyyy) ____ / ____ / ____ SPCFDT
(DCC to enter once confirmation notification received from Clinical Management Committee)

200. Date this form completed.....(dd/mmm/yyyy) ____ / ____ / ____

201. Username of person completing this form.....